- Home
- DIAX vs AUTL Comparison
DIAX vs AUTL Comparison
Compare DIAX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- AUTL
- Stock Information
- Founded
- DIAX 2005
- AUTL 2014
- Country
- DIAX United States
- AUTL United Kingdom
- Employees
- DIAX N/A
- AUTL N/A
- Industry
- DIAX Finance Companies
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DIAX Finance
- AUTL Health Care
- Exchange
- DIAX Nasdaq
- AUTL Nasdaq
- Market Cap
- DIAX 523.0M
- AUTL 625.4M
- IPO Year
- DIAX N/A
- AUTL 2018
- Fundamental
- Price
- DIAX $14.33
- AUTL $2.60
- Analyst Decision
- DIAX
- AUTL Strong Buy
- Analyst Count
- DIAX 0
- AUTL 5
- Target Price
- DIAX N/A
- AUTL $9.32
- AVG Volume (30 Days)
- DIAX 96.6K
- AUTL 1.5M
- Earning Date
- DIAX 01-01-0001
- AUTL 08-07-2025
- Dividend Yield
- DIAX 7.93%
- AUTL N/A
- EPS Growth
- DIAX N/A
- AUTL N/A
- EPS
- DIAX N/A
- AUTL N/A
- Revenue
- DIAX N/A
- AUTL $9,011,000.00
- Revenue This Year
- DIAX N/A
- AUTL $471.17
- Revenue Next Year
- DIAX N/A
- AUTL $115.34
- P/E Ratio
- DIAX N/A
- AUTL N/A
- Revenue Growth
- DIAX N/A
- AUTL N/A
- 52 Week Low
- DIAX $12.80
- AUTL $1.11
- 52 Week High
- DIAX $15.12
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- DIAX 54.01
- AUTL 60.99
- Support Level
- DIAX $14.17
- AUTL $2.39
- Resistance Level
- DIAX $14.38
- AUTL $2.61
- Average True Range (ATR)
- DIAX 0.11
- AUTL 0.13
- MACD
- DIAX -0.01
- AUTL -0.02
- Stochastic Oscillator
- DIAX 32.50
- AUTL 51.63
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.